Oney Zuniga, MD
Nephrology · Rockville, MDNPI 1689658627
Payments from drug & device makers
Across 163 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$1K
- Vifor Pharma, Inc.$517
- Acadia Pharmaceuticals Inc$493
- Sanofi-aventis U.S. LLC$294
- Otsuka America Pharmaceutical, Inc.$190
- AstraZeneca$157
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,93797%
- Education$1283%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 51 | $1,108 |
| Vifor Pharma, Inc. | 22 | $517 |
| Acadia Pharmaceuticals Inc | 7 | $493 |
| Sanofi-aventis U.S. LLC | 3 | $294 |
| Otsuka America Pharmaceutical, Inc. | 12 | $190 |
| AstraZeneca | 8 | $157 |
| Sumitomo Pharma America, Inc. | 7 | $157 |
| Avanir Pharmaceuticals, Inc. | 9 | $145 |
| Novartis | 3 | $118 |
| Sun Pharmaceutical Industries Inc. | 1 | $115 |
| Novo Nordisk | 6 | $98 |
| GSK | 4 | $93 |
| Amgen(2 entities) | 4 | $86 |
| Lilly USA, LLC | 4 | $81 |
| Pfizer | 3 | $77 |
| Bayer | 2 | $44 |
| Cumberland Pharmaceuticals, Inc. | 2 | $44 |
| Kerecis Limited | 1 | $36 |
| Melinta Therapeutics, LLC | 2 | $31 |
| Nevro Corp. | 1 | $27 |
| Eisai Inc. | 1 | $26 |
| Travere Therapeutics, Inc. | 4 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $17 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Normatec Industries, LP | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$455
- APTIOM$244
- DRIZALMA SPRINKLE$115
- EZALLOR SPRINKLE$115
- KAPSPARGO$115
How this compares
$4,064 in reported general payments places this provider in the 75th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 538 | $193,777 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 27 | $113,202 |
| AptiomEslicarbazepine Acetate | 113 | $70,063 |
| NuedextaDextromethorphan Hbr/Quinidine | 74 | $53,604 |
| TrulicityDulaglutide | 48 | $38,703 |
| JanuviaSitagliptin Phosphate | 23 | $24,689 |
| FarxigaDapagliflozin Propanediol | 29 | $21,306 |
| VraylarCariprazine Hcl | 13 | $19,914 |
| OzempicSemaglutide | 19 | $19,661 |
| Astagraf XlTacrolimus | 11 | $18,210 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 46 | $15,084 |
| XareltoRivaroxaban | 43 | $14,357 |
| AranespDarbepoetin Alfa In Polysorbat | 34 | $14,014 |
| TivicayDolutegravir Sodium | 13 | $13,714 |
| RexultiBrexpiprazole | 11 | $13,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Retacrit | $77 | $201,981568 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $1,108 | $70,063113 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $145 | $53,60474 claims |
| Lilly USA, LLCTrulicity | $81 | $38,70348 claims |
| AstraZenecaFarxiga | $157 | $21,30629 claims |
| Novo NordiskOzempic | $98 | $19,66119 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $93 | $16,18531 claims |
| AmgenAranesp | $86 | $14,01434 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $190 | $13,20511 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $157 | $11,58725 claims |
| NovartisEntresto | $118 | $8,73725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 285 nephrology providers in Maryland.
Other nephrology in Rockville
- Jeffrey PerlmutterRockville$7K
- Sandesh JoshiRockville$5K
- Stephen VaccarezzaRockville$5K
- Christopher SperatiBaltimore$1.5M
- Michelle EstrellaBaltimore$1.2M
- Mohamed AttaBaltimore$1.1M
- Chirag ParikhBaltimore$1M
- Mario BelledonnePotomac$715K
- Matthew WeirBaltimore$518K
- Kiran SamindlaFrederick$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.